Phase II Study of Platinum (Cisplatin/Carboplatin)and Polymeric Micelles Paclitaxel(Pm-Pac) With Ivonescimab in First Line Metastatic Squamous NSCLC.

NCT07009925 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Squamous Cell Lung Cancer

Interventions

DRUG: Ivonescimab 20mg/kg intravenous every 3 weeks

Sponsor

Jiangsu Cancer Institute & Hospital